Synergistic antitumor effect of CXCL10 with hyperthermia

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 6, 2008, Pages 679-687

  Chen, Ping ^a   Yang, Ling Lin ^a   Yang, Han Shuo ^a   Wang, Yong Sheng ^a   Li, Gang ^a   Wu, Yang ^a   Fang, Fang ^a   Liu, Kang ^a   Li, Jie ^a   Zhao, Xia ^a   Hu, Huo Zhen ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antitumor; Chemokine; CXCL10; Hyperthermia; Interferon inducible protein 10

Indexed keywords

CD31 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FIBROSARCOMA; HYPERTHERMIA; IMMUNOFLUORESCENCE TEST; LYMPHOCYTIC INFILTRATION; MEMORY CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL TIME; T CELL DEPLETION; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR NECROSIS; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CHEMOKINE CXCL10; COMBINED MODALITY THERAPY; FEMALE; HEAT-SHOCK PROTEINS; HYPERTHERMIA, INDUCED; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES;

EID: 41849138991     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0337-3     Document Type: Article

References (44)

1. Amir A, Kenneth EL, Axel S, Heike Z, Frank K, Daniel P, Alexandra R, Xiaohong H, Martin K, Marc B, Philip H, Hermann-Josef G et al (2003) Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63:8890-8898
2. Andrew LF, Josef F, Titia EL, Steven KL, Dominique L, Marshall SM, Ewa MT, Stephen MH, Richard AH (2002) Retroviral gene transfer of interferon-γ-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 99:149-153
3. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM (1996) Interferon-γ- inducible protein (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastasis. J Exp Med 184:981-992
4. Arenberg DA, White ES, Burdick MD, Strom SR, Strieter RM (2001) Improved survival in tumor-bearing SCIDmice treated with interferon-γ-inducible protein 10(IP-10/ CXCL10). Cancer Immunol Immunother 50:533-538
5. Baggiolini M (1998) Chemokines and leukocyte traffic. Nature 392:565-568
6. Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Ann Rev Immunol 15:675-705
7. Barrett JR (1997) Chemokines. Blood 90:909-928
8. Ben-sasson SA, Sherman Y, Gavrieli Y (1995) Identification of dying cells-in situ staining. Methods Cell Biol 46:29-39
9. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808-812
10. Bernhard VS, Olivier M, Wei-Jian Z, John M, Savio LCW (2000) Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. PNAS 97:4802-4807
11. Calderwood SK, Theriault JR, Gong J (2005) Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol 35:2518-2527
12. Cristina R, Luca P, Donatella V, Anna C, Paul D, Peter C, Pietro G, Federico B (2003) Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor. Cancer Res 63:1500-1507
13. Dewey WC (1994) Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 10:457-483
14. Falk MH, Issels RD (2001) Hyperthermia in oncology. Int J Hyperthermia 17:1-18
15. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27-31
16. Frank P, Arndt van O, William HM (2005) Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells. Cancer Res 65:4836-4843
17. Gang L, Ling T, Jian-mei H, Zhen-yu D, Qiu-ming H, Ping F, Yan-junW, Fei X, BingY, Ru Z, Feng P, Yu J et al (2005) Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand10 with cisplatin in solid tumors. Clin Cancer Res 11:4217-4224
18. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
19. Helena JM, Nader NH, Michael AB, David HG, Mary-Jane S, Kerri AS, Kevin B, Ruth H, Stephen G, Mohanraj D, Gerald AS, Vikas PS et al (1998) Weichselbaum. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394:287-291
20. Ji-yan L, Yu-quan W, Li Y, Xia Z, Ling T, Jian-mei H, Ting N, Fen L, Yu J, Bing H, Yang W, Jing-mei S et al (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102:1815-1823
21. Kampinga HH, Dikomey E (2001) Hyperthermic radiosensitization: mode of action and clinical relevance. Int J Radiat Biol 77:399-408
22. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:475-481
23. Leonidas GK, Teresa Z-K, Edward CH, Kenneth C, James VS, Joshua MF (2001) Cytokine-responsive gene-2/IFN-inducible protein-10 expression in multiple models of liver and bile duct injury suggests a role in tissue regeneration. J Immunol 167(1):399-406
24. Li C-Y, Dewhirst MW (2002) Hyperthermia-regulated immunogene therapy. Int J Hyperthermia 18:586-596
25. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and Mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963-969
26. Luster A (1998) Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 228:436-445
27. Manjili MH, Wang X-Y, Park J, Macdonald IJ, Li Y, van Schie RCAA, Subjeck JR (2002) Cancer immunotherapy: stress proteins and hyperthermia. Int J Hyperthermia 18:506-520
28. Mototsugu K, Shin'ichi Y, Tatsumasa M, Yasumasa N, Shuuichi K, Naotoshi H, Keiko S, Keisuke S, Masahiro H (2001) The effects of KNK437, a novel inhibitor of heat shock protein synthesis, on the acquisition of thermotolerance in a murine transplantable tumor in vivo. Clin Cancer Res 7:215-219
29. Multhoff IG (2002) Activation of natural killer cells by heat shock protein 70. Int J Hyperthermia 18:576-585
30. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA (2000) International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 52(1):145-176
31. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM (1995) Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 345:540-543
32. Peto R, Peto J (1972) A symptotically efficient rank invariant procedures. J R Stat Soc 135:185-207
33. Rau B, Wust P, Hohenberger P, Loffel J, Hunerbein M, Below C, Gellermann J, Speidel A, Vogl T, Riess H, Felix R, Schlag PM (1998) Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer: a phase II clinical trial. Ann Surg 227:380-389
34. Robert MS, Peter JP, Steven LK, Douglas AA, Marie DB, James K, Judith D, Jo Van D, Alfred W, David M, Sham-Yuen C, Steven R et al (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 270:27348-27357
35. Song CW (1984) Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 44:4721-4730
36. Srivastava P (2002) Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2:185-194
37. Teicher BA, Sotomayor EA, Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52:6702-6704
38. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H (2002) HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 277:15107-15112
39. Wessalowski R, Kruck H, Pape H, Kahn T, Willers R, Gobel R (1998) Hyperthermia for the treatment of patients with malignant germ cell tumors. Cancer 82:793-800
40. Xiao-ling X, Ru-han J, Ding-ping Y, Guo-hua D (2006) Irbesartan attenuates contrast media-induced NRK-52E cells apoptosis. Pharmacol Res 54:253-260
41. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
42. Yao L, Pike SE, Pittaluga S, Cherney P, Gupta G, Jaffe ES, Tosato G (2002) Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 51:358-366
43. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S (2000) Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60:2190-2196
44. Yu-Quan W, Qing-Ru W, Xia Z, Li Y, Ling T, You L, Bin K, Chong-Jiu L, Mei-Juan H, Yan-Yan L, Fei X, Qiu-Ming H et al (2000) Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 6:1160-1166